We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Myriad to Acquire Assurex
News

Myriad to Acquire Assurex

Myriad to Acquire Assurex
News

Myriad to Acquire Assurex

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Myriad to Acquire Assurex"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Myriad Genetics has announced that it has signed a definitive agreement to acquire Assurex Health, a global leader in genetic testing for psychotropic medicine selection, for $225 million upfront with the potential for $185 million in additional performance-based milestones. Assurex generated revenue of more than $60 million and tested more than 150,000 patients in Myriad's fiscal year 2016.

The transaction is expected to close at the end of Myriad's first quarter of fiscal year 2017. Myriad will provide financial guidance pertaining to the acquisition when the Company hosts its fourth-quarter earnings call on August 9, 2016.  A discussion on the details and strategy underlying this acquisition will be provided on a conference call today at 4:30 pm EDT.

"Assurex provides Myriad access to GeneSight® one of the fastest growing new diagnostic tests ever in a multi-billion dollar global market and builds upon Myriad's commitment to expand into neuroscience, positioning us for long-term growth," said Mark C. Capone, president and CEO, Myriad Genetics. "Importantly, this acquisition provides an experienced commercial organization in the neuroscience market that we believe will be one of the highest growth areas for personalized medicine and completes our infrastructure expansion consistent with our four-in-six strategy."

"We are excited as a fellow pioneering company to be joining the global leader in personalized medicine," said Virginia C. Drosos, president and CEO, Assurex Health.  "As one of the world's leading molecular diagnostic companies, Myriad has the reimbursement, regulatory and commercial expertise to expand the long-term potential of Assurex's neuroscience products and ensure even more patients can benefit from better outcomes through our diagnostic tests."

Advertisement